INCA035784 / Incyte - LARVOL DELTA

Preclinical Evaluation of INCA035784, a Novel T Cell–Redirecting Antibody for the Treatment of Calreticulin Mutation–Driven Myeloproliferative Neoplasms (SOHO 2026) - "Targeting the conserved mutCALR Ndomain with INCA035784 may have advantages over C-terminal–directed therapies, especially in patients harboring atypical mutCALR variants and those with canonical type 1/2 mutCALR. CD: cluster of differentiation."

Preclinical • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • CALR • CD34 • MPL

INCA035784: Data from P1 trial (NCT07008118) for myelofibrosis in Q1 2027 (Incyte) - Q2 2026 Results

P1 data • Hematological Malignancies • Myelofibrosis • Oncology

PRECLINICAL EVALUATION OF INCA035784, A NOVEL T-CELL–REDIRECTING ANTIBODY FOR THE TREATMENT OF MUTCALR-DRIVEN MYELOPROLIFERATIVE NEOPLASMS (MPNS) (EHA 2026) - "However, INCA035784 induced cytotoxicity of CD34 + HSPCs with autologous T cells in this patient sample. Summary/Conclusion These findings suggest that INCA035784, by targeting the conserved mutCALR N-domain, may have advantages over C-terminal– directed therapies, especially in patients harboring atypical mutCALR variants in addition to patients with canonical Type 1/2 mut CALR ."

Preclinical • Essential Thrombocythemia • Fibrosis • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Thrombocytosis • CALR • CD34 • MPL

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress (Businesswire) - "Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session; Oral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with myeloproliferative neoplasms (MPNs)."

CALR • JAK2V617F • P1 data • P3 data • Preclinical • Chronic Myeloid Leukemia • Diffuse Large B Cell Lymphoma • Essential Thrombocythemia • Follicular Lymphoma • Myelofibrosis • Myeloproliferative Neoplasm

INCA035784: Data readout from P1 trial (NCT07008118) for myelofibrosis in 2027 (Incyte, 44th Annual J.P. Morgan Healthcare Conference)

P1 data • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

INCA035784: Data readout from P1 trial (NCT07008118) for myelofibrosis in 2027 (Incyte, 44th Annual J.P. Morgan Healthcare Conference)

P1 data • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Myeloproliferative Neoplasm • Oncology

INCA035784, A NOVEL, EQUIPOTENT T CELL–REDIRECTING ANTIBODY FOR PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS CARRYING DIFFERENT TYPES OF CALRETICULIN MUTATIONS (EHA 2025) - "INCA035784 does not bind to wtCALR when a stress agent such as doxorubicin induces its translocation to the cell surface...INCA035784 induced minimal levels of CRS-associated cytokines from HD PBMCs, HD T cells, and patient-derived PBMCs vs other T cell-engaging antibodies such as mosunetuzumab and vibecotamab, targeting CD20 and CD123, respectively... Overall, INCA035784 activates T cells in the presence of mutCALR complexed with TPOR on the cell surface. By binding to a unique, conserved epitope on the mutCALR N-domain, INCA035784 can target the diverse mutCALR variants found across the MPN patient population. INCA035784 also exhibits a low-risk profile with respect to cytokine induction."

Clinical • Myeloproliferative Neoplasm • Oncology • CALR • CD123 • CD34 • CD69 • IL2RA • IL3RA • MPL

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Incyte Corporation

New P1 trial • Myeloproliferative Neoplasm • Oncology